Table IV.
Correlation between EGFR and HER2 in the studied primary tumor and metastasis samples.
| HER2 (patient number)
|
||||
|---|---|---|---|---|
| EGFR | 0 | 1+ | 2+ | 3+ |
| Primary tumor | ||||
| 0 | - | 6 | 3 | - |
| 1+ | 11 | 5,7 | 9,10 | - |
| 2+ | 1 | 8 | - | 12 |
| 3+ | - | 2,4 | - | - |
| Metastasis | ||||
| 0 | 9,11 | - | 3,5,6,10 | - |
| 1+ | - | - | - | |
| 2+ | 1,8 | - | - | 12 |
| 3+ | - | - | 2,7 | 4 |
Patients with positive expression in both EGFR and HER2 are marked with italics and underlined. For the primary tumors this was the case for only patient 12, while patients 2, 4, 7 and 12 had positive expression of both EGFR and HER2 in their analyzed metastases, indicating that only these are candidates for combined EGFR- and HER2-targeted therapy. Patient numbers are as listed in Table I. EGFR, epidermal growth factor receptor.